

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

THE TRUSTEES OF COLUMBIA )  
UNIVERSITY IN THE CITY OF NEW )  
YORK and )  
QIAGEN SCIENCES, LLC, )

Plaintiffs, )

v. )

ILLUMINA, INC. )

Defendant. )

Civil Action No. 19-1681-CFC

**JURY TRIAL DEMANDED**

**AMENDED COMPLAINT FOR PATENT INFRINGEMENT**

Plaintiffs The Trustees of Columbia University in the City of New York (“Columbia University”) and QIAGEN Sciences, LLC (“QIAGEN”) (collectively “Plaintiffs”), by and through their undersigned counsel, for their Amended Complaint against Defendant Illumina, Inc. (“Illumina”), allege as follows:

**THE PARTIES**

1. Plaintiff Columbia University is one of the world’s leading institutions of higher education, located at 535 West 116th Street, New York, New York 10027. It is a non-profit educational corporation formed by special act of the Legislature of the State of New York.

2. Plaintiff QIAGEN Sciences, LLC is a Delaware company having its principal place of business at 19300 Germantown Road, Germantown, MD 20874. QIAGEN Sciences, LLC is the successor-in-interest to QIAGEN Waltham, Inc. as of December 31, 2017.

Columbia Ex. 2029  
Illumina, Inc. v. The Trustees  
of Columbia University  
in the City of New York  
IPR2020-01177

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

THE TRUSTEES OF COLUMBIA )  
UNIVERSITY IN THE CITY OF NEW )  
YORK and )  
QIAGEN SCIENCES, LLC, )

Plaintiffs, )

v. )

ILLUMINA, INC. )

Defendant. )

Civil Action No. 19-1681-CFC

**JURY TRIAL DEMANDED**

**AMENDED COMPLAINT FOR PATENT INFRINGEMENT**

Plaintiffs The Trustees of Columbia University in the City of New York (“Columbia University”) and QIAGEN Sciences, LLC (“QIAGEN”) (collectively “Plaintiffs”), by and through their undersigned counsel, for their Amended Complaint against Defendant Illumina, Inc. (“Illumina”), allege as follows:

**THE PARTIES**

1. Plaintiff Columbia University is one of the world’s leading institutions of higher education, located at 535 West 116th Street, New York, New York 10027. It is a non-profit educational corporation formed by special act of the Legislature of the State of New York.

2. Plaintiff QIAGEN Sciences, LLC is a Delaware company having its principal place of business at 19300 Germantown Road, Germantown, MD 20874. QIAGEN Sciences, LLC is the successor-in-interest to QIAGEN Waltham, Inc. as a result of a merger effective December 31, 2017.

3. Upon information and belief, Defendant Illumina, Inc. is a Delaware corporation having its principal place of business at 5200 Illumina Way, San Diego, California 92122.

### **JURISDICTION AND VENUE**

4. This action arises under the Patent Laws of the United States of America, 35 U.S.C. § 1 *et seq.*

5. This Court has subject matter jurisdiction over this action under 28 U.S.C. § 1331 and 28 U.S.C. § 1338(a) because this is a civil action arising under the Patent Act.

6. This Court has personal jurisdiction over Illumina because Illumina is incorporated in the State of Delaware.

7. Venue is proper in this District under 28 U.S.C. § 1400(b) because Illumina is incorporated in the State of Delaware and thus resides in this District.

### **BACKGROUND**

#### **The Patents-in-Suit**

8. On September 10, 2019, the United States Patent and Trademark Office (“USPTO”) duly issued United States Patent No. 10,407,458 (“the ’458 Patent”), entitled “Massive Parallel Method for Decoding DNA and RNA,” in the names of inventors Jingyue Ju, Zengmin Li, John Robert Edwards, and Yasuhiro Itagaki. A true and correct copy of the ’458 Patent is attached hereto as Exhibit 1.

9. On September 10, 2019, the USPTO duly issued United States Patent No. 10,407,459 (“the ’459 Patent”), entitled “Massive Parallel Method for Decoding DNA and RNA,” in the names of inventors Jingyue Ju, Zengmin Li, John Robert Edwards, and Yasuhiro Itagaki. A true and correct copy of the ’459 Patent is attached hereto as Exhibit 2.

10. On October 1, 2019, the USPTO duly issued United States Patent No. 10,428,380 (“the ’380 Patent”), entitled “Massive Parallel Method for Decoding DNA and RNA,” in the

names of inventors Jingyue Ju, Zengmin Li, John Robert Edwards, and Yasuhiro Itagaki. A true and correct copy of the '380 Patent is attached hereto as Exhibit 3.

11. On October 8, 2019, the USPTO duly issued United States Patent No. 10,435,742 (“the '742 Patent”), entitled “Massive Parallel Method for Decoding DNA and RNA,” in the names of inventors Jingyue Ju, Zengmin Li, John Robert Edwards, and Yasuhiro Itagaki. A true and correct copy of the '742 Patent is attached hereto as Exhibit 4.

12. On October 29, 2019, the USPTO duly issued United States Patent No. 10,457,984 (“the '984 Patent”), entitled “Massive Parallel Method for Decoding DNA and RNA,” in the names of inventors Jingyue Ju, Zengmin Li, John Robert Edwards, and Yasuhiro Itagaki. A true and correct copy of the '984 Patent is attached hereto as Exhibit 5.

13. Columbia University owns by assignment all right, title, and interest in and to the '458 Patent, the '459 Patent, the '380 Patent, the '742 Patent, and the '984 Patent (collectively “the Patents-in-Suit”).

14. QIAGEN is the exclusive licensee of the Patents-in-Suit.

15. On January 31, 2019, the applications that issued as the '458 Patent, the '380 Patent, and the '742 Patent published as US2019/0031704, US2019/0031706, and US2019/0031705, respectively.

16. On March 21, 2019, the applications that issued as the '459 Patent and the '984 Patent published as US2019/0085014 and US2019/0085015 (collectively with US2019/0031704, US2019/0031706, and US2019/0031705, “the Published Applications”).

17. The inventions as claimed in the Patents-in-Suit are identical to the inventions as claimed in the Published Applications.

18. Illumina is a large and sophisticated company that has been a party to patent

litigation with Columbia University and QIAGEN, and thus, on information and belief, Illumina monitors patent applications involving DNA sequencing technology and was aware of the content of each of the claims of the '458 Patent, the '380 Patent, and the '742 Patent on or after they were published on January 31, 2019, and the content of each of the claims of the '459 Patent and the '984 Patent on or after they were published on March 21, 2019.

### **Nucleotides and DNA Sequencing**

19. The Patents-in-Suit relate to modified versions of nucleotides (known as “nucleotide analogues”) and methods of using such nucleotide analogues for sequencing DNA (deoxyribonucleic acid). DNA encodes the genetic information of living organisms. DNA consists of smaller building blocks called nucleotides; the sequence of the nucleotides determines hereditary traits in living organisms. DNA sequencing—*i.e.*, determining the order of the nucleotides in a DNA strand—is of enormous importance for a wide variety of applications in medicine, biotechnology, and other fields. For example, by sequencing the DNA of individuals with a particular disease or the DNA in tumor cells, medical researchers and physicians may learn the genetic basis for the disease or tumor and may design or provide therapies specifically targeted to it.

20. A nucleotide consists of a sugar, a base, and one or more phosphate groups, as shown below. Nucleotides are identified by their bases, which form the genetic code of DNA. There are four different nucleotide bases—an adenine (“A”), a guanine (“G”), a cytosine (“C”), and a thymine (“T”). A and G are known as “purine” bases, while C and T are “pyrimidine” bases. The sugar in the nucleotide contains five carbon atoms, conventionally numbered 1' through 5'. When the nucleotide is found in isolation, a hydroxyl group (OH) is attached at the 3' position and is referred to as the 3'-OH group (circled below). The nucleotide depicted below is called a deoxyribonucleotide triphosphate.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.